Advanced chemoresistant colorectal cancer
Conditions
Interventions
trial group:Aspirin + FOLFOX4
Sponsors
The Fourth Affiliated Hospital, Soochow University
Eligibility
Sex/Gender
All
Age
26 Years to 72 Years
Inclusion criteria
Inclusion criteria: Eligible patients had histologically proven metastatic colorectal adenocarcinoma with documented progressive disease after first-line and second-line chemotherapy. Patients developing metastatic disease within 6 months of receiving adjuvant therapy were also included. Other criteria for eligibility included measurable disease by Response Evaluation Criteria in Solid Tumors Group criteria, had a period of at least 4 weeks since their last round of chemotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Laboratory criteria include WBC count>=3.5*10^9/L, neutrophil count>=1.5*10^9/L, platelet count >=100*10^9/L, haemoglobin level>=9g/dL, serum bilirubin level<=2.0mg/dL, serum AST/ALT and alkaline phosphatase level<=2 times the upper limit of normal, the serum creatinine level <=1.5mg/dL.
Exclusion criteria
Exclusion criteria: aspirin hypersensitivity, digestive ulcer or active bleeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effect rate; | — |
Countries
China
Contacts
Public ContactShujian Chang
Outcome results
None listed